Palliative care and Parkinson's disease : meeting summary and recommendations for clinical research

Introduction: Palliative care is an approach to caring for patients and families affected by serious illnesses that focuses on the relief of suffering through the management of medical symptoms, psychosocial issues, advance care planning and spiritual wellbeing. Over the past decade there has been an emerging clinical and research interest in the application of palliative care approaches to Parkinson’s disease (PD) and outpatient palliative care services are now offered by several movement disorders centers. Methods: An International Working Group Meeting on PD and Palliative Care supported by the Parkinson’s Disease Foundation was held in October 2015 to review the current state of the evidence and to make recommendations for clinical research and practice. Results: Topics included: 1) Defining palliative care for PD; 2) Lessons from palliative care for heart failure and other chronic illnesses; 3) Patient and caregiver Needs; 4) Needs assessment tools; 5) Intervention strategies; 6) Predicting prognosis and hospice referrals; 7) Choice of appropriate outcome measures; 8) Implementation, dissemination and education research; and 9) Need for research collaborations. We provide an overview of these discussions, summarize current evidence and practices, highlight gaps in our knowledge and make recommendations for future research. Conclusions: Palliative Care for PD is a rapidly growing area which holds great promise for improving outcomes for PD patients and their caregivers. While clinical research in this area can build from lessons learned in other diseases, there is a need for observational, methodological and interventional research to address the unique needs of PD patients and caregivers

Pregnancies and associated events in women receiving Enzyme Replacement Therapy for late onset Glycogen Storage Disease Type II (Pompe disease)

AIM: Glycogen storage disease type II (GSD II or Pompe disease; OMIM; 232 300) is a rare autosomal recessive lysosomal storage disorder resulting from deficiency of α-glucosidase and accumulation of glycogen in muscle. Clinical symptoms include weakness of skeletal and respiratory muscles and, in infants, cardiomyopathy. Patients with GSD II receive infusions of recombinant α-glucosidase (enzyme replacement therapy; ERT), which slow the progression of the disease. ERT is given to male and female patients of all ages but as yet little is documented on the effects of continuing ERT during pregnancy. The aim of this case series was therefore to ascertain the pregnancy outcomes of women with GSD II on ERT and to describe adverse events associated with pregnancy, delivery and therapy. METHODS: The medical records of eight women attending the Royal Free Hospital Lysosomal Storage Disorders Unit were reviewed. Four of the eight women had seven pregnancies over a period of 8 years. RESULTS: In this series GSD II was associated with interventional deliveries but normal neonates. Cessation of ERT in early pregnancy resulted in deterioration of maternal symptoms and emergence of allergic reactions on restarting ERT. CONCLUSION: Individualized care plans are required to ensure the best neonatal and maternal outcomes. Consideration should be given to the potential benefits to mother and fetus of continuing ERT during pregnancy

JNK and NF-κB Cell Signaling Pathways in Cardiovascular Disease Present Potential Targets for Curcumin Therapy

Curcumin (diferuloylmethane) is a compound derived from the rhizomes of Curcumin longa that has been long used for medicinal purposes. Curcumin alleviates the pathology of cardiovascular diseases, including atherosclerosis, aneurysm, and cardiomyopathy. The mechanism of curcumin therapy is under active research. The NF-κB and JNK pathways are two that curcumin interacts with to block inflammatory processes, apoptosis, and fibrotic tissue remodeling to prevent the pathologies of cardiovascular disease. While curcumin has demonstrated powerful mediation of cardiovascular disease, its bioavailability in body tissues is limited due to the instability and hydrophobicity of its structure. Further work is underway to stabilize curcumin in vivo and enhance its biodistribution using plant compounds like piperine, nanoemulsions, and nanoparticles

Palliative care in Parkinson's disease : developing a needs assessment tool

Background: Parkinson’s disease (PD) is a common, life-limiting, neurodegenerative condition. Despite calls for improved access to palliative care, provision is lacking, due in part to poor understanding and recognition of palliative care needs. Where services exist, negotiating the chronic-palliative interface is challenging. Aims: 1) To establish the palliative needs of people living with PD. 2) To adapt and clinimetrically test a palliative assessment tool for PD. Method: A sequential mixed method design was adopted: Aim 1: Systematic review and synthesis of qualitative evidence and primary qualitative study (focus groups and semi-structured interviews). Combined findings used to adapt a palliative care assessment tool for Parkinson’s disease. Aim 2: Face and content validity tested by expert panel. Construct validity examined in 50 people with PD and their carers. Inter-rater reliability examined in broad range of clinicians using video consultations. Results: Aim 1 – Four lines of argument were identified: i) Information tension, ii) care tension, iii) interpersonal negotiations, iv) intra-personal negotiations. The response to diagnosis, carer vigilance and presence of disease milestones were highlighted. Aim 2 - Construct validity was good (tau B > 0.6) for two constructs, moderate (>0.4) for five and fair (>0.2) for the remainder. Reliability as measured by kappa was moderate (kappa >0.4) for four, fair (>0.2) for five and poor for four constructs. Two constructs with poor kappa are explained by extremely high percentage agreement. Conclusions: Adaptation of the NAT:Parkinson’s disease has been successful, with clinimetric properties supporting use by a range of clinicians. Future studies should examine utility within integrated services